The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...
SHERBET, an individual patient data post hoc pooled analysis of 5 prospective trials, compared HDR-BT with SBRT in patients with intermediate-risk prostate cancer.
Health care access and disparities: A multidimensional and interdisciplinary approach to foster awareness in cancer clinical trials. Enrollment demographics vs GU onc, county, and state.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results